|
|
|
|
|
|
|
M T W Thu F |
|
10 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Our annual Endpoints 11 gala is coming up fast, where we'll announce our picks for this year's most compelling, cutting-edge companies across biotech. Kyle LaHucik takes a look back at the 77 previous winners to see which ones have thrived and which haven’t. Tickets to this year’s Sept. 24 dinner in Boston and Sept. 28 virtual experience are available here. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
We'll be unveiling this year's Endpoints 11 in Boston on the night of Sept. 24. Join us. The biopharma industry feels much different than... | |
|
|
|
|
|
|
by Max Gelman
|
The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday. An epilepsy study of the experimental drug called BHV-7000... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Tevard Biosciences, Disc Medicine, InduPro, EMD Serono and Frazier Life Sciences. Shionogi fails mid-stage stroke trial: The company’s experimental drug redasemtide didn’t... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
BridgeBio Oncology Therapeutics' share price BBOT plummeted by about 24% at market close Wednesday on the back of plans that it is scaling back its... | |
|
|
|
|
|
|
by Anna Brown
|
The UK government's move to pay more for medicines and foster a closer relationship with drugmakers appears to have led to an increase in the... | |
|
|
|
|
|
